Top Markets
#1 Islamic Coin Islamic Coin +151.47%
#2 DOVU DOVU +49.98%
#3 Black Phoenix Black Phoenix +34.71%
#4 Velvet Velvet +26.93%
#5 DoubleZero DoubleZero +13.36%
#6 Akedo Akedo +13.09%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.82%
#8 HOME HOME +11.04%
#9 Cross Cross +10.90%
#10 Fake World Assets Fake World Assets +9.95%
Coin of the day
Islamic Coin Islamic Coin
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Histogen Inc. Histogen Inc.

Histogen Inc.

HSTO
Kedudukan dalam Saham #40870
Histogen Inc. operates as a clinical-stage biotechnology company, focusing on... Histogen Inc. operates as a clinical-stage biotechnology company, focusing on the development of novel, stem cell-free biologic products derived from its proprietary hypoxia-generated growth factor technology platform. Among its offerings is HST-003, a human extracellular matrix, currently undergoing Phase 1/2 clinical trials to mend articular cartilage defects in the knee. Additionally, the company is advancing HST-004, a cell-conditioned media solution designed for spinal disc repair, and Emricasan, an orally active pan-caspase inhibitor targeting COVID-19 treatment. In its preclinical pipeline, Histogen is developing CTS-2090 and CTS-2096. These are selective caspase-1 inhibitors formulated to suppress inflammasome activation and intervene in a range of inflammation-mediated conditions. Founded in 2007, Histogen Inc. maintains its headquarters in San Diego, California.
Harga Saham
$0.02765
Disegerakkan terakhir: 2024-12-23
Modal Pasaran
$69.04K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Histogen Inc. (HSTO)

Kategori

Healthcare
Pendapatan untuk Histogen Inc. (HSTO)
Pendapatan pada Sep 2023 TTM: $-12.38M
Menurut laporan kewangan terkini Histogen Inc., pendapatan semasa syarikat ialah $-12.38M. Pada tahun 2021, syarikat memperoleh pendapatan sebanyak $-15.01M, peningkatan berbanding pendapatan pada tahun 2020 yang berjumlah $-18.82M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Histogen Inc. dari 2011 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-12.38M 16.35%
2022 $-10.64M -29.08%
2021 $-15.01M -20.24%
2020 $-18.82M 65.28%
2019 $-11.39M -36.79%
2018 $-18.01M 3.53%
2017 $-17.40M -41.49%
2016 $-29.73M 23.12%
2015 $-24.15M 8.19%
2014 $-22.32M 42.93%
2013 $-15.62M 78.48%
2012 $-8.75M -27.07%
2011 $-12.00M 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -42,694.48%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -15,851.37%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -24,370.97%
BE